Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new research that helps define clinically meaningful improvement in overall health reported by people living with tardive dyskinesia who ...
Neurocrine's expanding drug portfolio could drive substantial growth through 2031.
Neurocrine Biosciences, Inc. announced new research that helps define clinically meaningful improvement in overall health reported by people living with tardive dyskinesia who were treated with ...
On October 7, 2026, Cerevance announced the top-line results of the Phase 3 ARISE trial for the investigational Parkinson's ...
An oral drug designed to treat the core symptoms of autism spectrum disorder, has been dubbed by some as 'the Ozempic of ...
Dr. Ning Xu of Tsinghua University lost his Nikon microscopy prize when researchers found AI-generated artifacts in his cilia ...
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 2 clinical study of investigational ...
Squats help increase overall strength, balance, and mobility while preventing injuries and making everyday activities easier. Variations include bodyweight squats (basic, wall, pistol), weighted ...
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 2 clinical study of investigational compound NBI-1117567 (NBI-'567) in adults with mild to moderate Alzheimer's ...
The Movement Project is a project of Yale Law School that seeks to reform migration laws and frameworks to advance the interests of working people, manage climate and demographic change, function at a ...
The brain-first versus body-first model proposes that Lewy body disease can originate from different pathogenic routes, accounting for heterogeneity in symptoms, neurodegeneration patterns and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results